NCT01766219View on ClinicalTrials.gov

CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

April 30, 2018

Study Completion Date

May 18, 2018

Conditions
Adult Primary Cholangiocellular CarcinomaAdvanced Adult Primary Liver CancerCholangiocarcinoma of the Extrahepatic Bile DuctCholangiocarcinoma of the GallbladderLocalized Unresectable Adult Primary Liver CancerMetastatic Extrahepatic Bile Duct CancerRecurrent Adult Primary Liver CancerRecurrent Extrahepatic Bile Duct CancerUnresectable Extrahepatic Bile Duct Cancer
Interventions
DRUG

6,8-bis(benzylthio)octanoic acid

Given IV

Trial Locations (1)

27157

Comprehensive Cancer Center of Wake Forest University, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT01766219 - CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter